IN2015DN02912A - - Google Patents

Download PDF

Info

Publication number
IN2015DN02912A
IN2015DN02912A IN2912DEN2015A IN2015DN02912A IN 2015DN02912 A IN2015DN02912 A IN 2015DN02912A IN 2912DEN2015 A IN2912DEN2015 A IN 2912DEN2015A IN 2015DN02912 A IN2015DN02912 A IN 2015DN02912A
Authority
IN
India
Prior art keywords
pi3k
oxazolidin
phosphatidylinositol
kinase
inhibitors
Prior art date
Application number
Inventor
Robin Alec Fairhurst
Pascal Furet
Frank Stephan Kalthoff
Andreas Lerchner
Heinrich Rueeger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2015DN02912A publication Critical patent/IN2015DN02912A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to oxazolidin- 2- one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol- 3- kinase) inhibitors , as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions , diseases and disorders dependent on PI3K.
IN2912DEN2015 2012-11-12 2013-11-11 IN2015DN02912A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725113P 2012-11-12 2012-11-12
PCT/IB2013/060052 WO2014072956A1 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives

Publications (1)

Publication Number Publication Date
IN2015DN02912A true IN2015DN02912A (en) 2015-09-11

Family

ID=49667527

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2912DEN2015 IN2015DN02912A (en) 2012-11-12 2013-11-11

Country Status (43)

Country Link
US (3) US9296733B2 (en)
EP (2) EP2922848B1 (en)
JP (1) JP6262245B2 (en)
KR (1) KR102153763B1 (en)
CN (1) CN104718204B (en)
AP (1) AP2015008347A0 (en)
AR (1) AR093408A1 (en)
AU (1) AU2013343022B2 (en)
BR (1) BR112015010136A2 (en)
CA (1) CA2890942C (en)
CL (1) CL2015001202A1 (en)
CO (1) CO7380758A2 (en)
CR (1) CR20150248A (en)
CU (1) CU24365B1 (en)
CY (1) CY1119391T1 (en)
DK (1) DK2922848T5 (en)
EA (2) EA027987B1 (en)
EC (1) ECSP15025093A (en)
ES (1) ES2641820T3 (en)
HK (1) HK1209108A1 (en)
HR (1) HRP20171425T1 (en)
HU (1) HUE034492T2 (en)
IL (1) IL238239A (en)
IN (1) IN2015DN02912A (en)
JO (1) JO3334B1 (en)
LT (1) LT2922848T (en)
MA (1) MA38076A1 (en)
MX (1) MX363436B (en)
MY (1) MY174239A (en)
NZ (1) NZ706591A (en)
PE (1) PE20151006A1 (en)
PH (1) PH12015501053A1 (en)
PL (1) PL2922848T3 (en)
PT (1) PT2922848T (en)
RS (1) RS56336B1 (en)
SG (1) SG11201503447QA (en)
SI (1) SI2922848T1 (en)
TN (1) TN2015000120A1 (en)
TW (1) TWI608005B (en)
UA (1) UA114001C2 (en)
UY (1) UY35128A (en)
WO (1) WO2014072956A1 (en)
ZA (1) ZA201502175B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX342326B (en) 2011-09-27 2016-09-26 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh.
UY34632A (en) 2012-02-24 2013-05-31 Novartis Ag OXAZOLIDIN- 2- ONA COMPOUNDS AND USES OF THE SAME
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
ES2665619T3 (en) 2013-03-14 2018-04-26 Novartis Ag 3-Pyrimidin-4-yl-oxazolidin-2-ones as mutant HDI inhibitors
AU2016325446B2 (en) * 2015-09-24 2021-05-13 Drexel University Novel compositions and methods for treating or preventing dermal disorders
MX2018014167A (en) 2016-05-18 2019-08-16 Piqur Therapeutics Ag Treatment of skin lesions.
TW201929861A (en) 2017-11-06 2019-08-01 瑞士商諾華公司 Formulation comprising oxazolidin-2-one-pyrimidine derivative
WO2022053651A2 (en) 2020-09-10 2022-03-17 Precirix N.V. Antibody fragment against fap
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB581334A (en) 1943-09-29 1946-10-09 Francis Henry Swinden Curd New pyrimidine compounds
JPS4921148B1 (en) 1970-12-28 1974-05-30
JPS4921149B1 (en) 1970-12-28 1974-05-30
AT340933B (en) 1973-08-20 1978-01-10 Thomae Gmbh Dr K PROCESS FOR THE PRODUCTION OF NEW PYRIMIDE DERIVATIVES AND THEIR ACID ADDITIONAL SALTS
DE2341925A1 (en) 1973-08-20 1975-03-06 Thomae Gmbh Dr K 2,4, (opt.5-), 6-substd. pyriminidines as antithrombic agents - e.g. 6-methyl-5-nitro-2-piperazino-4-thiomorpolino-pyrimidine
US4994386A (en) 1987-07-13 1991-02-19 Pharmacia Diagnostics, Inc. Production of HBLV virus in the HSB-2 cell line
US4929726A (en) 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
EP0330263A1 (en) 1988-02-25 1989-08-30 Merck & Co. Inc. Piperazinylalkylpyrimidines as hypoglycemic agents
GB9012311D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
ATE139117T1 (en) 1990-07-03 1996-06-15 Mitsui Petrochemical Ind PYRIMIDINE COMPOUND AND ITS PHARMACEUTICALLY ACCEPTABLE SALT
US5786355A (en) 1995-04-13 1998-07-28 Taiho Pharmaceutical Co., Ltd. 4,6-diarylpyrimidine derivatives and salts thereof
JP3734907B2 (en) 1996-12-19 2006-01-11 富士写真フイルム株式会社 Development processing method
EP1020462B1 (en) 1997-07-24 2004-02-11 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compounds and antitumor agent containing the same as active ingredient
JPH11158073A (en) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd Adenosine a3 antagonist
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6150362A (en) 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
DK0930302T3 (en) 1998-01-16 2003-07-21 Hoffmann La Roche Benzosulfone derivatives
US6417185B1 (en) 1998-06-19 2002-07-09 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6495558B1 (en) 1999-01-22 2002-12-17 Amgen Inc. Kinase inhibitors
EP1144390A2 (en) 1999-01-22 2001-10-17 Amgen Inc., Kinase inhibitors
AU5889100A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
JP2003523942A (en) 1999-06-30 2003-08-12 メルク エンド カムパニー インコーポレーテッド SRC kinase inhibitor compounds
CA2376957A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
IL147395A0 (en) 1999-07-15 2002-08-14 Pharmacopeia Inc Bradykinin b1 receptor antagonists
JP2001089452A (en) 1999-09-22 2001-04-03 Sankyo Co Ltd Pyrimidine derivative
CA2400447C (en) 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
GB2361236B (en) 2000-03-29 2002-04-24 Cyclacel Ltd Pyrimidines useful against proliferative disorders
WO2001083456A1 (en) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
CN1657523A (en) 2000-04-28 2005-08-24 田边制药株式会社 Cyclic compounds
US6599926B2 (en) 2000-06-23 2003-07-29 Bristol-Myers Squibb Company Heteroaryl-phenyl substituted factor Xa inhibitors
KR100860827B1 (en) 2000-09-06 2008-09-30 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 Inhibitors of glycogen synthase kinase 3
KR100876069B1 (en) 2000-09-15 2008-12-26 버텍스 파마슈티칼스 인코포레이티드 Pyrazole Compounds Useful as Protein Kinase Inhibitors and Pharmaceutical Compositions Comprising the Same
SE0004053D0 (en) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
MXPA03005610A (en) 2000-12-21 2003-10-06 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors.
EP1363890A4 (en) 2001-02-07 2009-06-10 Ore Pharmaceuticals Inc Melanocortin-4 receptor binding compounds and methods of use thereof
WO2002064096A2 (en) 2001-02-16 2002-08-22 Tularik Inc. Methods of using pyrimidine-based antiviral agents
JP2004531571A (en) 2001-05-25 2004-10-14 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Carbamate and oxamide compounds as inhibitors of cytokine production
WO2002102313A2 (en) 2001-06-19 2002-12-27 Bristol-Myers Squibb Company Pyrimidine inhibitors of phosphodiesterase (pde) 7
US6603000B2 (en) 2001-07-11 2003-08-05 Boehringer Ingelheim Pharmaceuticals, Inc. Synthesis for heteroarylamine compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
AU2003225800A1 (en) 2002-03-15 2003-09-29 Hayley Binch Azolylaminoazine as inhibitors of protein kinases
US20040009981A1 (en) 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
ES2289279T3 (en) 2002-03-15 2008-02-01 Vertex Pharmaceuticals Incorporated USEFUL COMPOSITIONS AS PROTEINQUINASE INHIBITORS.
WO2003077921A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azinylaminoazoles as inhibitors of protein kinases
US20040082627A1 (en) 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
JP2006510597A (en) 2002-09-27 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド Substituted pyrimidines
AU2003288925A1 (en) 2002-10-08 2004-05-04 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
KR101052482B1 (en) 2002-11-21 2011-07-28 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 2,4,6-trisubstituted pyrimidine, a phosphatidylinositol (PI) 3-kinase inhibitor, and their use in the treatment of cancer
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004084824A2 (en) 2003-03-24 2004-10-07 Merck & Co., Inc. Biaryl substituted 6-membered heterocyles as sodium channel blockers
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
CA2520323C (en) 2003-04-09 2013-07-09 Exelixis, Inc. Tie-2 modulators and methods of use
AU2004259712A1 (en) 2003-07-15 2005-02-03 Neurogen Corporation Substituted pyrimidin-4-ylamine analogues
US7566712B2 (en) 2003-07-16 2009-07-28 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
AR045944A1 (en) 2003-09-24 2005-11-16 Novartis Ag ISOQUINOLINE DERIVATIVES 1.4-DISPOSED
AU2005232745A1 (en) 2004-04-13 2005-10-27 Astellas Pharma Inc. Polycyclic pyrimidines as potassium ion channel modulators
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
MY145822A (en) 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
CA2587642C (en) * 2004-11-30 2013-04-09 Amgen Inc. Substituted heterocycles and methods of use
CN101080401A (en) 2004-12-13 2007-11-28 神经能质公司 Substituted biaryl analogues
WO2006065872A1 (en) 2004-12-13 2006-06-22 Neurogen Corporation Piperazinyl-pyridine analogues
ATE544748T1 (en) 2004-12-28 2012-02-15 Kinex Pharmaceuticals Llc COMPOSITIONS AND METHODS FOR THE TREATMENT OF CELL PROLIFERATION DISEASES
AU2006206246A1 (en) 2005-01-19 2006-07-27 Neurogen Corporation Heteroaryl substituted piperazinyl-pyridine analogues
CA2599320A1 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
CA2606288A1 (en) 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
WO2007080382A1 (en) 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي PI-3 Kinase inhibitors and methods of their use
EP2012794B1 (en) * 2006-04-13 2014-09-17 The Trustees of Columbia University in the City of New York Compositions and intraluminal devices for inhibiting vascular stenosis
CL2007003847A1 (en) 2006-12-28 2008-04-18 Basf Ag COMPOUNDS DERIVED FROM PYRIMIDINS 2,4,5 TRI-SUBSTITUTES; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE FOR THE TREATMENT OF CANCER.
EP2118087B1 (en) 2007-02-06 2012-03-28 Novartis AG Pi 3-kinase inhibitors and methods of their use
US7957951B2 (en) 2007-03-16 2011-06-07 Robert Bosch Gmbh Address translation system for use in a simulation environment
KR20100031639A (en) 2007-07-09 2010-03-23 아스트라제네카 아베 Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2009066084A1 (en) 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
WO2009109605A1 (en) 2008-03-05 2009-09-11 Novartis Ag Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
RU2509558C2 (en) 2008-03-26 2014-03-20 Новартис Аг Imidazoquinoline and pyrimidine derivatives as potential modulators of vbgf-stimulated angiogenic processes
WO2009120094A2 (en) 2008-03-27 2009-10-01 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
US8575338B2 (en) 2008-04-09 2013-11-05 Mitsubishi Tanabe Pharma Corporation Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
JP2012506898A (en) 2008-10-31 2012-03-22 ノバルティス アーゲー Combination of phosphatidylinositol-3-kinase (PI3K) inhibitor and mTOR inhibitor
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010068863A2 (en) 2008-12-12 2010-06-17 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
JP5747440B2 (en) 2009-02-06 2015-07-15 住友化学株式会社 Hydrazide compound and its use for pest control
ES2453474T3 (en) 2009-02-06 2014-04-07 Nippon Shinyaku Co., Ltd. Aminopyrazine derivatives and corresponding medicine
MX346801B (en) 2009-03-13 2017-03-31 Agios Pharmaceuticals Inc Methods and compositions for cell-proliferation-related disorders.
WO2010120994A2 (en) 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
EP2432767B1 (en) 2009-05-19 2013-06-26 Dow AgroSciences LLC Compounds and methods for controlling fungi
EP2451802A1 (en) 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
EP2462123B1 (en) 2009-08-04 2013-10-02 Merck Sharp & Dohme Corp. 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
AR077999A1 (en) 2009-09-02 2011-10-05 Vifor Int Ag ANTIGONISTS OF PYRIMIDIN AND TRIAZIN-HEPCIDINE
RU2595718C2 (en) 2009-09-09 2016-08-27 Селджен Авиломикс Рисерч,Инк. Pi3-kinase inhibitors and use thereof
ES2642109T3 (en) 2009-12-09 2017-11-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized by having an IDH mutation
GB201004200D0 (en) 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
AR081626A1 (en) 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
WO2012009678A1 (en) 2010-07-16 2012-01-19 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their method of use
JP5998145B2 (en) 2010-10-01 2016-09-28 ノバルティス アーゲー Process for producing pyrimidine derivatives
NO2629776T3 (en) 2010-10-18 2018-01-13
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
CN103476765A (en) 2011-02-11 2013-12-25 达娜-法勃肿瘤研究所公司 Method of inhibiting hamartoma tumor cells
CN102827073A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Therapeutically active compositions and application methods thereof
US20140213583A1 (en) 2011-09-01 2014-07-31 Novartis Ag PI3K Inhibitor for Use in the Treatment of Bone Cancer or for Preventing Metastatic Dissemination Primary Cancer Cells into the Bone
MX342326B (en) 2011-09-27 2016-09-26 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh.
AU2012318874A1 (en) 2011-10-06 2014-05-15 Merck Sharp & Dohme Corp. 1,3-substituted azetidine PDE10 inhibitors
UY34632A (en) 2012-02-24 2013-05-31 Novartis Ag OXAZOLIDIN- 2- ONA COMPOUNDS AND USES OF THE SAME
SG10201608469RA (en) * 2012-05-16 2016-11-29 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
CA2872541A1 (en) 2012-06-06 2013-12-12 Novartis Ag Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
WO2014028566A1 (en) 2012-08-16 2014-02-20 Novartis Ag Combination of pi3k inhibitor and c-met inhibitor
WO2014064058A1 (en) 2012-10-23 2014-05-01 Novartis Ag Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
BR112015022483A2 (en) 2013-03-14 2017-07-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as mutant idh inhibitors
ES2665619T3 (en) 2013-03-14 2018-04-26 Novartis Ag 3-Pyrimidin-4-yl-oxazolidin-2-ones as mutant HDI inhibitors
CN103483345B (en) 2013-09-25 2016-07-06 中山大学 PI3K inhibitors of kinases, the pharmaceutical composition comprising it and application thereof
CN103694218B (en) 2013-12-05 2016-04-27 中山大学 Pyrimidine compound, PI3K inhibitor, the pharmaceutical composition comprising PI3K inhibitor and application

Also Published As

Publication number Publication date
CR20150248A (en) 2015-07-01
JO3334B1 (en) 2019-03-13
EP3199158B1 (en) 2019-04-17
TN2015000120A1 (en) 2016-06-29
MY174239A (en) 2020-04-01
DK2922848T5 (en) 2017-10-30
CN104718204B (en) 2017-11-28
CA2890942C (en) 2021-01-12
EA201590929A1 (en) 2015-08-31
KR20150082295A (en) 2015-07-15
UA114001C2 (en) 2017-04-10
ES2641820T3 (en) 2017-11-14
EP2922848A1 (en) 2015-09-30
ECSP15025093A (en) 2019-03-29
EA027987B1 (en) 2017-09-29
EA201790289A1 (en) 2017-06-30
HK1209108A1 (en) 2016-03-24
UY35128A (en) 2014-06-30
JP2015536974A (en) 2015-12-24
ZA201502175B (en) 2018-05-30
US20190382399A1 (en) 2019-12-19
TW201427974A (en) 2014-07-16
CN104718204A (en) 2015-06-17
US10202371B2 (en) 2019-02-12
AU2013343022A1 (en) 2015-04-23
RS56336B1 (en) 2017-12-29
PL2922848T3 (en) 2017-12-29
NZ706591A (en) 2016-03-31
IL238239A (en) 2017-05-29
AU2013343022B2 (en) 2015-08-20
MA38076A1 (en) 2018-02-28
BR112015010136A2 (en) 2017-07-11
CY1119391T1 (en) 2018-02-14
DK2922848T3 (en) 2017-10-09
HUE034492T2 (en) 2018-02-28
MX363436B (en) 2019-03-22
EP2922848B1 (en) 2017-06-28
PH12015501053B1 (en) 2015-07-27
US20140135330A1 (en) 2014-05-15
WO2014072956A1 (en) 2014-05-15
PE20151006A1 (en) 2015-07-04
LT2922848T (en) 2017-09-25
CL2015001202A1 (en) 2015-07-03
PH12015501053A1 (en) 2015-07-27
AR093408A1 (en) 2015-06-03
SG11201503447QA (en) 2015-05-28
EP3199158A1 (en) 2017-08-02
CA2890942A1 (en) 2014-05-15
CU20150050A7 (en) 2015-11-27
SI2922848T1 (en) 2017-10-30
MX2015005914A (en) 2015-09-08
TWI608005B (en) 2017-12-11
CU24365B1 (en) 2018-10-04
CO7380758A2 (en) 2015-09-10
EA029714B1 (en) 2018-05-31
JP6262245B2 (en) 2018-01-17
US9296733B2 (en) 2016-03-29
KR102153763B1 (en) 2020-09-09
AP2015008347A0 (en) 2015-04-30
HRP20171425T1 (en) 2017-11-17
PT2922848T (en) 2017-10-05
US20160168145A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
PH12014501900A1 (en) Oxazolidin-2-one compounds and uses thereof as pi3ks inhibitors
AU2018236800B2 (en) DNA-PK inhibitors
PH12015501053B1 (en) Oxazolidin-2-one-pyrimidine derivatives
PH12016501160A1 (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
IN2014KN02601A (en)
EA024842B9 (en) Compounds as modulators of pi3k protein kinase
UA117830C2 (en) Bipyrazole derivatives as jak inhibitors
MD20150071A2 (en) Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of CNS and other disorders
EA201692313A1 (en) Derivatives of indolysine as inhibitors of phosphosinositide-3-kinase
MX2017013137A (en) Chromene derivatives as phoshoinositide 3-kinases inhibitors.
MX366829B (en) Itraconazole compositions and dosage forms, and methods of using the same.
AU2012312301A8 (en) Compounds useful as inhibitors of choline kinase
TN2014000340A1 (en) Oxazolidin- 2 -one compounds and uses thereof as pi3ks inhibitors
MX2015012393A (en) Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases.